Evidence map›Paper›PMID 36881874›Full record

ArticleJournal of immunology (Baltimore, Md. : 1950)2023

Ablation of SYK Kinase from Expanded Primary Human NK Cells via CRISPR/Cas9 Enhances Cytotoxicity and Cytokine Production.

James D Dahlvang, Jenna K Dick, Jules A Sangala, Philippa R Kennedy, Emily J Pomeroy, Kristin M Snyder, Juliette M Moushon, Claire E Thefaine, Jianming Wu, Sara E Hamilton and 6 more

Open access · greenAbstract read
In one paragraph

Article in Journal of immunology (Baltimore, Md. : 1950), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
2.3field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 14 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Review
  6. Article
  7. New insights into SYK targeting in solid tumors.Trends in pharmacological sciences · 2024
    Review
  8. Article
  9. Article
  10. Review
  11. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors at 1 institution in 1 country.

James D DahlvangDivision of Infectious Disease and International Medicine, Department of Medicine, University of Minnesota, Minneapolis, MN.ORCID 0000-0002-2702-6943
Jenna K DickDivision of Infectious Disease and International Medicine, Department of Medicine, University of Minnesota, Minneapolis, MN.ORCID 0000-0003-2553-7536
Jules A SangalaDivision of Infectious Disease and International Medicine, Department of Medicine, University of Minnesota, Minneapolis, MN.ORCID 0000-0002-6432-4966
Philippa R KennedyCenter for Immunology, University of Minnesota, Minneapolis, MN.ORCID 0000-0003-0239-5440
Emily J PomeroyMasonic Cancer Center, University of Minnesota, Minneapolis, MN.ORCID 0000-0001-7690-3570
Kristin M SnyderCenter for Immunology, University of Minnesota, Minneapolis, MN.
Juliette M MoushonDivision of Infectious Disease and International Medicine, Department of Medicine, University of Minnesota, Minneapolis, MN.ORCID 0000-0002-6871-0872
Claire E ThefaineCenter for Immunology, University of Minnesota, Minneapolis, MN.ORCID 0000-0003-2162-4325
Jianming WuMasonic Cancer Center, University of Minnesota, Minneapolis, MN.ORCID 0000-0001-9142-7066
Sara E HamiltonCenter for Immunology, University of Minnesota, Minneapolis, MN.ORCID 0000-0002-3768-7622
Martin FelicesCenter for Immunology, University of Minnesota, Minneapolis, MN.ORCID 0000-0002-5945-0634
Jeffrey S MillerCenter for Immunology, University of Minnesota, Minneapolis, MN.ORCID 0000-0002-0339-4944
Bruce WalcheckCenter for Immunology, University of Minnesota, Minneapolis, MN.ORCID 0000-0003-1933-3887
Beau R WebberMasonic Cancer Center, University of Minnesota, Minneapolis, MN.
Branden S MoriarityMasonic Cancer Center, University of Minnesota, Minneapolis, MN.
Geoffrey T HartDivision of Infectious Disease and International Medicine, Department of Medicine, University of Minnesota, Minneapolis, MN.ORCID 0000-0003-0483-307X
University of Minnesota · US

Funding

Trial Design and Biostatistical Support CoreP01CA065493 · NCI · UNIVERSITY OF MINNESOTA TWIN CITIES · PI Mark J Osborn · 1995 to 2026
$48.2M
Therapeutic Potential of Adaptive NK Cells in Cancer and TransplantationP01CA111412 · NCI · UNIVERSITY OF MINNESOTA TWIN CITIES · PI MILLER, JEFFREY S. · 2005 to 2025
$38.2M
IMMUNOLOGY TRAINING PROGRAMT32AI007313 · NIAID · UNIVERSITY OF MINNESOTA TWIN CITIES · PI Carla Rothlin · 1989 to 2026
$5.7M
Activated NK CAR Cells to Cure HIVR01AI161017 · NIAID · UNIVERSITY OF MINNESOTA · PI MORIARITY, BRANDEN S, SKINNER, PAMELA J · 2021 to 2025
$3.8M
The role of natural killer cells and antibodies in protection from malariaR01AI146031 · NIAID · UNIVERSITY OF MINNESOTA · PI HART, GEOFFREY T · 2020 to 2024
$2.7M
Regulation of the Immune Response to Plasmodium by IL-10 Producing Natural Killer CellsR01AI143828 · NIAID · UNIVERSITY OF MINNESOTA · PI HAMILTON HART, SARA ELIZABETH · 2019 to 2023
$2.3M
Engineered B Cells as a Universal Platform for the Treatment of EnzymopathiesR01AI146009 · NIAID · UNIVERSITY OF MINNESOTA · PI MORIARITY, BRANDEN S · 2020 to 2024
$1.9M
Multiplex Engineered Human Lymphocytes for Therapeutic Protein DeliveryR21AI163731 · NIAID · UNIVERSITY OF MINNESOTA · PI WEBBER, BEAU RICHARD · 2021 to 2022
$426k
Determining the mechanism of antibody-mediated parasite clearance in Plasmodium blood stage infectionR21AI149659 · NIAID · UNIVERSITY OF MINNESOTA · PI HART, GEOFFREY T · 2020 to 2021
$424k
NCI NIH HHS P01 CA065493NCI NIH HHS P01 CA111412NIAID NIH HHS R01 AI143828NIAID NIH HHS R01 AI146009NIAID NIH HHS R01 AI146031NIAID NIH HHS R01 AI161017NIAID NIH HHS R21 AI149659NIAID NIH HHS R21 AI163731NIAID NIH HHS T32 AI007313
6 · The paper itself

Abstract

CMV infection alters NK cell phenotype and function toward a more memory-like immune state. These cells, termed adaptive NK cells, typically express CD57 and NKG2C but lack expression of the FcRγ-chain (gene: FCER1G, FcRγ), PLZF, and SYK. Functionally, adaptive NK cells display enhanced Ab-dependent cellular cytotoxicity (ADCC) and cytokine production. However, the mechanism behind this enhanced function is unknown. To understand what drives enhanced ADCC and cytokine production in adaptive NK cells, we optimized a CRISPR/Cas9 system to ablate genes from primary human NK cells. We ablated genes that encode molecules in the ADCC pathway, such as FcRγ, CD3ζ, SYK, SHP-1, ZAP70, and the transcription factor PLZF, and tested subsequent ADCC and cytokine production. We found that ablating the FcRγ-chain caused a modest increase in TNF-α production. Ablation of PLZF did not enhance ADCC or cytokine production. Importantly, SYK kinase ablation significantly enhanced cytotoxicity, cytokine production, and target cell conjugation, whereas ZAP70 kinase ablation diminished function. Ablating the phosphatase SHP-1 enhanced cytotoxicity but reduced cytokine production. These results indicate that the enhanced cytotoxicity and cytokine production of CMV-induced adaptive NK cells is more likely due to the loss of SYK than the lack of FcRγ or PLZF. We found the lack of SYK expression could improve target cell conjugation through enhanced CD2 expression or limit SHP-1-mediated inhibition of CD16A signaling, leading to enhanced cytotoxicity and cytokine production.

Indexed as

CytomegalovirusCytomegalovirus InfectionsAntibody-Dependent Cell CytotoxicityCRISPR-Cas SystemsCytokinesHumansKiller Cells, NaturalSyk KinaseCytokinesSyk KinaseSYK protein, human

Identifiers

PMID36881874
PMCPMC10073313
OpenAlexW4323351305

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.